This compound is an Fmoc-protected amino acid derivative featuring a terminal alkene and a chiral center. It is primarily used as a building block in solid-phase peptide synthesis and pharmaceutical intermediate manufacturing.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 288617-75-4
3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)propanoic acid
Fmoc-protected amino acid building block
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-6-(1,3-dioxoisoindolin-2-yl)hexanoic acid
Fmoc-protected amino acid building block
(2S)-6-azido-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)hexanoic acid
Fmoc-protected amino acid building block
Fmoc-4-(tert-butoxycarbonylmethoxy)-L-phenylalanine
Fmoc-protected amino acid building block
Diazepam N-oxide
Pharmaceutical intermediate for impurity synthesis
6,7-Dimethoxyquinazoline-2,4(1H,3H)-dione
pharmaceutical intermediate for alpha1-blockers
Lifitegrast Impurity 125
Pharmaceutical impurity reference standard
N-(5-((Diphenylphosphoryl)methyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide
Pharmaceutical intermediate
(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-2-methyldec-9-enoic acid
MADFVGMQNXRFAF-SANMLTNESA-N
C[C@](CCCCCCC=C)(C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13